NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced guidance today regarding the Company’s planned pivotal Phase III trial for palifosfamide in metastatic soft tissue sarcoma, including details of the proposed study’s design, timing and regulatory review.
